Macquarie Group
VIR icon

Macquarie Group’s Vir Biotechnology VIR Stock Holding History

Macquarie Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,731
Closed -$54K – 2134
2022
Q3 		$54K Sell
1,731
-1,087
-39% -$27.6K ﹤0.01% 1941
2022
Q2 		$72K Hold
2,818
– – ﹤0.01% 1956
2022
Q1 		$72K Hold
2,818
– – ﹤0.01% 2037
2021
Q4 		$118K Buy
2,818
+2,210
+363% +$86.6K ﹤0.01% 1885
2021
Q3 		$26K Buy
+608
New +$26.3K ﹤0.01% 2396

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Macquarie Group's VIR Position: Q4 2022 in Review

Macquarie Group sold out of Vir Biotechnology (VIR) in Q4 2022, closing a stake of 1,731 shares — an estimated $54K sold.

Macquarie Group first reported a position in VIR in Q3 2021 and held it in 5 quarters. The position peaked at $118K in Q4 2021. 223 funds tracked by Wall St. Rank hold VIR as of Q4 2022.

  • Macquarie Group reported no remaining Vir Biotechnology position as of Q4 2022 after selling out during the quarter.
  • Macquarie Group sold 1,731 Vir Biotechnology shares in Q4 2022, an estimated $54K.
  • Macquarie Group first reported a position in Vir Biotechnology in Q3 2021 and held it in 5 quarters.
  • Macquarie Group's Vir Biotechnology position peaked at $118K in Q4 2021.
  • 223 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.